Tuna Mutis

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Editorial: Understanding and controlling adverse effects in myeloma patients treated with T cell redirecting immunotherapies.

Editorial: Understanding and controlling adverse effects in myeloma patients treated with T cell redirecting immunotherapies.

Journal: Frontiers in immunology

Published: April 02, 2026

Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells.

Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells.

Journal: Frontiers in immunology

Published: November 29, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.

Journal: British journal of haematology

Published: August 06, 2025

Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.

Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.

Journal: Experimental hematology & oncology

Published: July 28, 2025

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: June 06, 2025

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Journal: HemaSphere

Published: March 17, 2025

Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Journal: Blood cancer journal

Published: February 16, 2025

A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.

A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.

Journal: Blood

Published: January 27, 2025

Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.

Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration.

Journal: Materials today. Bio

Published: November 11, 2024

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

Journal: HemaSphere

Published: October 11, 2024

Showing 1-12 of 101

Last Updated: 09/26/2026